secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001558370-22-008420
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022
--------------------------------------------------------------------------------

- Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.
- Cash, cash equivalents and restricted cash totaled $180.0M at March 31, 2022.
- Pemvidutide Phase 2 MOMENTUM obesity trial enrolling ~320 subjects; interim 24-week data expected Q4 2022.
- Phase 1b NAFLD trial enrollment completed; 12-week liver fat and weight loss data expected Q3 2022.
- HepTcell Phase 2 chronic hepatitis B trial continuing; data readout expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/0001558370-22-008420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/alt-20220512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer